Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

Cited In for PubMed (Select 16043801)

1.

Cell Therapy Strategies vs. Paracrine Effect in Huntington's Disease.

Im W, Kim M.

J Mov Disord. 2014 Apr;7(1):1-6. doi: 10.14802/jmd.14001. Epub 2014 Apr 30. Review.

2.

Neuroprotective effects of psychotropic drugs in Huntington's disease.

Lauterbach EC.

Int J Mol Sci. 2013 Nov 15;14(11):22558-603. doi: 10.3390/ijms141122558. Review.

3.

Tracking motor impairments in the progression of Huntington's disease.

Long JD, Paulsen JS, Marder K, Zhang Y, Kim JI, Mills JA; Researchers of the PREDICT-HD Huntington's Study Group.

Mov Disord. 2014 Mar;29(3):311-9. doi: 10.1002/mds.25657. Epub 2013 Oct 21.

4.

Treatment of huntington disease.

Videnovic A.

Curr Treat Options Neurol. 2013 Aug;15(4):424-38. doi: 10.1007/s11940-013-0219-8.

5.

Monitoring Huntington's disease progression through preclinical and early stages.

Tang C, Feigin A.

Neurodegener Dis Manag. 2012 Aug 1;2(4):421-435.

6.

Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.

Armstrong MJ, Miyasaki JM; American Academy of Neurology.

Neurology. 2012 Aug 7;79(6):597-603. doi: 10.1212/WNL.0b013e318263c443. Epub 2012 Jul 18.

7.

Nucleic Acid-Based Therapy Approaches for Huntington's Disease.

Vagner T, Young D, Mouravlev A.

Neurol Res Int. 2012;2012:358370. doi: 10.1155/2012/358370. Epub 2012 Jan 11.

8.

Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.

Zádori D, Klivényi P, Plangár I, Toldi J, Vécsei L.

J Cell Mol Med. 2011 Apr;15(4):701-17. doi: 10.1111/j.1582-4934.2010.01237.x. Review.

9.

Therapeutic Strategies in Huntington's Disease.

Kanazawa I.

J Clin Neurol. 2006 Dec;2(4):213-24. doi: 10.3988/jcn.2006.2.4.213. Epub 2006 Dec 20.

10.

Mouse models of Huntington disease: variations on a theme.

Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR.

Dis Model Mech. 2009 Mar-Apr;2(3-4):123-9. doi: 10.1242/dmm.002451.

12.

Altered lipid metabolism in brain injury and disorders.

Adibhatla RM, Hatcher JF.

Subcell Biochem. 2008;49:241-68. doi: 10.1007/978-1-4020-8831-5_9. Review.

13.

Fatty acids and neuropsychiatric disorders.

Puri BK.

BMC Psychiatry. 2008 Apr 17;8 Suppl 1:S1. doi: 10.1186/1471-244X-8-S1-S1. No abstract available.

14.

Neuroprotection for Huntington's disease: ready, set, slow.

Hersch SM, Rosas HD.

Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003. Review.

15.

Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS.

Ann Clin Psychiatry. 2008 Jan-Mar;20(1):1-3. doi: 10.1080/10401230701844802.

16.

Role of Lipids in Brain Injury and Diseases.

Adibhatla RM, Hatcher JF.

Future Lipidol. 2007 Aug;2(4):403-422.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk